ADA Conference Highlights Obesity Drug Competition and Clinical Gaps
The American Diabetes Association's annual conference featured discussions on intensifying competition in the obesity drug market and emerging clinical blind spots in diabetes care. Industry presentations covered new entrants challenging established GLP-1 medications and provider challenges in translating clinical trial data to real-world patient populations. The conference highlighted ongoing shifts in the diabetes and obesity treatment landscape that affect formulary management and utilization patterns. These developments have implications for managed care organizations managing pharmacy spend and clinical protocols.
Medicaid MCOs face rising pharmacy costs from obesity and diabetes medications, requiring updated prior authorization protocols and formulary strategies as new competitors enter the market.
Pharmacy · Managed Care
You might also like